CLOSEOUT LETTER

Weidenhamer And Morin Enterprise March 16, 2016

Recipient:: Weidenhamer And Morin Enterprise; United States

Issuing Office:: United States


Department of Health and Human Services	Food and Drug Administration
	Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring, MD 20993

MAR 16 2016

VIA UPS and Electronic Mail

Michael Weidenhamer
Weidenhamer & Morin Enterprises L.L.C.
LiQuiVape
67 South Lake Street
Forest Lake, MN 55025
Walleyemike2787@gmail.com

Dear Mr. Weidenhamer:

The United States Food and Drug Administration's (FDA) Center for Tobacco Products has completed an evaluation of your corrective actions included in your letter, received March 1, 2016, in response to our Warning Letter dated February 24, 2016. Based on our evaluation, it appears that you have addressed the violation contained in the Warning Letter on http://www.liquivapeus.com.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.

Sincerely,

/S/

Sangeeta V. Chatterjee
Branch Chief
Division of Promotion, Advertising, and Labeling
Office of Compliance and Enforcement
Center for Tobacco Products

VIA Electronic Mail
cc:

liquivapeus1@gmail.com

abuse@godaddy.com

Department of Health and Human Services